Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| K01DA062708 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
Not provided
This study examines the effects of e-cigarette (EC) flavors among adults with opioid use disorder (OUD) receiving buprenorphine treatment who currently use e-cigarettes. Participants will smell and rate 11 EC flavors based on appeal, sensory characteristics, and likelihood of future use. Researchers will examine how different flavor profiles influence the appeal and reinforcing effects of ECs in this population. The goal is to identify EC flavors that may enhance the acceptability of ECs as a potential harm-reduction strategy among adults with OUD receiving buprenorphine treatment.
This study examines the effects of e-cigarette (EC) flavors among adults with opioid use disorder (OUD) who are receiving buprenorphine treatment and currently use e-cigarettes. Participants will complete a brief session in which they will smell and rate 11 EC flavors based on their appeal, sensory characteristics, and likelihood of future use. Researchers will examine how different flavor profiles influence the appeal, positive subjective effects, and reinforcing potential of EC flavors in this population. The goal of the study is to identify one or more EC flavors that may enhance the acceptability and reinforcing effects of ECs as a potential harm-reduction strategy among adults with OUD receiving buprenorphine treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sweet-cooling | Drug | Sweet-cooling EC flavor | ||
| Sweet non-cooling EC flavor | Drug | Sweet non-cooling flavor | ||
| Tobacco flavor EC | Drug | Tobacco flavor EC |
| Measure | Description | Time Frame |
|---|---|---|
| Perceived Sweetness | Perceived sweetness of each e-cigarette flavor will be assessed using a one-item VAS ranging from "Not sweet at all" to "Extremely sweet," with higher scores indicating greater perceived sweetness. | Baseline session |
| Perceived Coolness/Freshness | Perceived coolness/freshness of each e-cigarette flavor will be assessed using a one-item VAS ranging from "Not cool/fresh at all" to "Extremely cool/fresh," with higher scores indicating greater perceived coolness/freshness. | Baseline session |
| Perceived Flavor Strength | Perceived flavor strength will be assessed using a one-item VAS ranging from "Very weak" to "Very strong," with higher scores indicating greater perceived flavor strength. | Baseline session |
| Perceived Harshness/Irritation | Perceived harshness/irritation of each e-cigarette flavor will be assessed using a one-item VAS ranging from "Not harsh/irritating at all" to "Extremely harsh/irritating," with higher scores indicating greater perceived harshness/irritation. | Baseline session |
| Flavor Liking | Flavor liking will be assessed using a one-item VAS ranging from "Not at all" to "Extremely," with higher scores indicating greater liking of the flavor. | Baseline session |
| Likelihood of Future Use | Likelihood of future use will be assessed using a one-item VAS ranging from "Not at all" to "Definitely," with higher scores indicating greater likelihood of future use of the flavor. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
-
Not provided
Not provided
Not provided
E-cigarette users with opioid use disorder receiving burpenorphine
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Irene Pericot-Valverde, PhD | Contact | 18549998005 | (864)656-4467 | iperico@clemson.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Prisma Health Recovery Clinic-Greenville | Recruiting | Greenville | South Carolina | 29605 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009293 | Opioid-Related Disorders |
| ID | Term |
|---|---|
| D000079524 | Narcotic-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline session |